| Biomarker ID | 224 |
| PMID | 17932343 |
| Year | 2007 |
| Biomarker | PAI-1(active) (Plasminogen Activator Inhibitor) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | OR - 0.81 |
| Effect on Pathways | Pathways Include:- Response to elevated platelet cytosolic calcium,Signaling by TGF-beta receptor complex, Complement and coagulation cascades,E2F transcription , SMAD2/3 nuclear pathwayfactor network |
| Experiment | Cancerous Vs Normal Patients |
| Type of Biomarker | Diagnostic |
| Cohort | 127 patients with Prostate Cancer were identified from SABORT cohort and correspondingly 127 age matched cohorts were chosen. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.581 |
| Accuracy | NA |
| Level Of Significance | p=0.01 |
| Method Used | LabMAP Technology |
| Clinical | No |
| Remarks | A total panel of 54 markers was evaluated to check whether they could differentiate between cases (Prostate Cancer) and age matched controls. They panel could not differentiate between the two. But the given markers were found differentially expressed between the two. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SERPINE1 |